---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009282"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:26:37.336580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC

## Summary
- Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.
- No dose-related increases in adverse events; neutropenia consistent with palbociclib plus endocrine therapy profile.
- Partial responses observed in 5 patients (1 confirmed, 4 unconfirmed); clinical benefit rate 42% (5/12 CBR-eligible).
- 59% of patients remain on treatment as of March 8, 2023 data cut-off; enrollment ongoing toward ~45 patients.
- OP-1250 showed favorable PK: 8-day half-life, dose-proportional exposure, no effect on palbociclib levels.

## SEC filing metadata
- accession: 0001558370-23-009282
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023009282/0001558370-23-009282-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023009282/olma-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009282
- JSON: https://secwatch.observer/filing/0001558370-23-009282.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009282.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.